azacitidine has been researched along with Diabetic Glomerulosclerosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Huang, Z; Li, R; Li, Z; Liang, X; Lin, T; Liu, S; Ma, J; Shi, W; Tan, X; Wang, W; Ye, Z; Yu, C; Zhang, B; Zhang, H; Zhang, L; Zhang, Q; Zhao, X | 1 |
| Chen, G; Chen, H; Dong, Z; Liu, H; Liu, Y; Ren, S; Sun, L; Tang, L; Xia, M; Zhang, L; Zhu, J | 1 |
| Cho, YH; Choi, HS; Kim, SY; Lee, HG; Lee, JH; Yoon, SY | 1 |
3 other study(ies) available for azacitidine and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury.
Topics: Albuminuria; Animals; Azacitidine; Binding Sites; Cell Line; Cell Movement; Cell Proliferation; Cytoprotection; Decitabine; Diabetes Mellitus; Diabetic Nephropathies; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Male; Mice, Inbred C57BL; Podocytes; Promoter Regions, Genetic; RNA Interference; Sp1 Transcription Factor; Time Factors; Transcription Factor RelA; Transfection | 2017 |
Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease.
Topics: Adolescent; Adoptive Transfer; Adult; Aged; Animals; Azacitidine; Cytosine; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Epigenesis, Genetic; Female; Gene Knockdown Techniques; Humans; Leukocytes, Mononuclear; Male; Mice; Middle Aged; Primary Cell Culture; Promoter Regions, Genetic; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Young Adult | 2019 |
Successful allogeneic stem-cell transplantation in a patient with myelodysplastic syndrome with hemodialysis-dependent end-stage renal disease.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Renal Dialysis; Risk; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous | 2011 |